The Vall d´Hebron Institute of Oncology (VHIO) Seeks a “Junior Group Leader in Hematooncology & Immunotherapy”
Reference: Ref. 48-2023
Application deadline: 01/06/2023
Number of vacancies: 1
Job description:
Vall d´Hebron Institute of Oncology (VHIO) is a cancer research center associated with Vall d’Hebron University Hospital that combines translational and clinical research to address the most pressing unmet needs in cancer research and patient care. For more information, including a description of the research programs, please visit: www.vhio.net
VHIO invites applications from outstanding young investigators interested in launching an independent research laboratory, with a particular emphasis on cell-based immunotherapy in hematological malignancies.
Research themes for this position include:
- Development of immune-based personalized therapeutics including CAR-T cells and other cellular therapies.
- Translational immunology using collected samples from more than 200 CAR T-cell patients.
- Drug-testing and development in partnership with several international companies.
What do we offer:
We offer the expertise of a leading team in the field of CAR T-cells and cellular therapy in Europe with ongoing research projects in partnership with leading institutions in Germany, France and United Kingdom.
The successful candidate will be provided with laboratory space, a competitive start-up package, and access to state-of-the-art core units and facilities (e.g.: genomics, proteomics, molecular pathology etc) to develop their research proposal. They will be expected to work within a highly collaborative and interdisciplinary environment in close interaction with researchers in the CAR-T Program and the Experimental Haematology group at VHIO.
Application:
Applicants should include a full CV (including bibliography and current/past competitive funding), a letter of intent, a brief (3-page max) research proposal, and the names of at least three references. Expressions of interest will be reviewed by the VHIO’s Internal Scientific Committee. Materials should be combined in a single PDF and sent by email to selecciorrhh@vhio.net
Applications will be immediately reviewed by the internal scientific committee and will be considered until June 1st, 2023.
About VHIO:
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), has established itself as a comprehensive cancer center of proven excellence internationally. It is also thanks to VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.
VHIO’s translation toward precision oncology: https://www.vhio.net
Vall d’Hebron Institute Oncology (VHIO) endorses the Requirements and Principles of the European Charter for Researchers, the Code of Conduct for the Recruitment of Researchers promoted by the European Commission and follows Equal Opportunities policies.
On 10th April 2018 VHIO was awarded the “HR Excellence in Research” logo. Our Institute was consequently granted permission to use the HR Excellence in Research Award logo as demonstration of its stimulating and favourable work environment in line with the Charter & Code.
